4C Medical Technologies
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6655 Wedgwood Rd N Ste 160, Maple Grove,...Website
www.4cmed.comRevenue
$11 MillionIndustry
About 4C Medical Technologies
4C Medical is a medical device company developing minimally invasive therapies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation (TR) therapy. The company's implant device candidate is the first MR therapy with supra-annular positioning and atrial-only fixation. It is designed to preserve the native mitral valve and left ventricle, eliminating all the known issues associated with transcatheter mitral valve replacement technologies in development today, which rely on placement and fixation in the native mitral annulus and left ventricle.Explore more
4C Medical Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to 4C Medical Technologies
Compare insights from companies similar to 4C Medical Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
4C Medical Technologies
$11M
11-50
Private
$224.3M
2015
JD
Jason DiederingVice President, Research Development & Operations
4C Medical Technologies Tech Stack
A closer look at the technologies used by 4C Medical Technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 4C Medical Technologies
Sign Up For FreeTo access detailed company insights
4C Medical is a medical device company developing minimally invasive therapies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation (TR) therapy. The company's implant device candidate is the first MR therapy with supra-annular positioning and atrial-only fixation. It is d... Read More
